Status:
RECRUITING
Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD
Lead Sponsor:
Peking University People's Hospital
Conditions:
Gastrointestinal Stromal Tumors
Minimal Residual Disease
Eligibility:
All Genders
Brief Summary
So far, MRD assessment by liquid biopsy (ctDNA) has not been used to predict postoperative treatment efficacy and recurrence risk of GIST patients because of special disease characteristics and techno...
Detailed Description
Assessing MRD (Minimal Residual Disease) and predicting the postoperative adjuvant treatment efficacy and recurrence risk of tumor patients based on ctDNA (circulating tumor DNA) detected by liquid bi...
Eligibility Criteria
Inclusion
- Patients aged between 18 and 80
- Patients suspected for high-risk GIST by preoperative imaging examinations or diagnosed with high-risk GIST by pathological biopsy, who have not received preoperative neoadjuvant treatment
- Patients must have not received any treatment including radiotherapy, chemotherapy or surgery
- The function of other organs including liver and kidneys is good enough so that the patients could tolerate targeted therapy and surgery
- Postoperative pathology conformed the diagnosis of high-risk GIST
- Patients and their families could understand the protocol of this study and voluntarily agree to participate in. Signed informed consents are required
Exclusion
- Previous medical history of malignant tumors or synchronous other malignancies
- Emergent surgery because of bowel obstruction, perforation or bleeding
- Pregnant or lactant women
- Medical history of severe mental illness
- Patients with contraindication for targeted therapy and surgery
- Non-R0 resection
- Postoperative pathology conformed the diagnosis of non-high-risk GIST
- Patients with distant metastasis
- Other situations in which researchers consider that the patient is unsuitable for this study
Key Trial Info
Start Date :
January 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2028
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05408897
Start Date
January 1 2022
End Date
April 1 2028
Last Update
September 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University People'S Hospital
Beijing, Beijing Municipality, China, 100044